IDH1 and malignant glioma: As we mentioned previously, the prominent genomic feature that mostly distinguishes LGG from malignant gliomas, such as GBM, is the mutational status of the two genes encoding the cytoplasmatic IDH1 and/or the mitochondrial IDH2, where ~80% of LGGs present IDH mutations, compared to only ~5% of GBMs.